14th Question of the Day July 8, 2014 Is TherapeuticsMD four lead products going to be huge game changer for compounding pharmacies and compounded hormones?

FBR Capital over-the-top bullish on TherapeuticsMD • 7:54 AM

• Shares of TherapeuticsMD (TXMD) are up 30% premarket on robust volume in apparent response to FBR Capital's Outperform rating and $34 PT, representing almost a seven-fold increase from the current price.
• The company focuses on women's health, specifically hormone replacement therapies. It's four lead products in development are TX 12-001HR (estradiol + progesterone) for hormone replacement and to treat the symptoms of menopause; TX 12-002HR (progesterone) for the treatment of amenorrhea; TX 12-003HR (estradiol) for the treatment of moderate-to-severe vasomotor symptoms due to menopause and TX 12-004HR (estradiol) for the treatment of vulvar and vaginal atrophy in postmenopausal women.
• Consensus revenue estimates for Q2 and Q3 are $3.1M and $3.2M, respectively. Consensus views for 2014 and 2015 are $12.5M and $15.6M, respectively.
• 146 mutual funds have positions, up from 89 a year earlier.

Read comments